Zoetis Inc. 8K

Zoetis Inc. agreed with its CFO Wetteny Joseph on his transition from EVP and CFO to Special Advisor to the CEO effective August 16, 2026, with a defined transition period, severance eligibility, and extensive release and restrictive covenant terms.

Zoetis Inc. entered into a letter agreement with its Executive Vice President and Chief Financial Officer, Wetteny Joseph, under which he will cease serving as EVP and CFO and as an executive officer as of the close of business on August 16, 2026 (or a later date determined by the company) and transition to a non-executive role as Special Advisor to the CEO on financial matters through a transition period ending no later than February 28, 2027, during which he will remain employed, continue to receive base salary and benefits, and assist in the orderly handoff of CFO responsibilities. Upon his eventual termination of employment (absent termination for cause), Mr. Joseph will be eligible for severance benefits under the company’s Executive Severance Plan and specified equity treatment as if his termination occurred in connection with a restructuring event, conditioned on his execution and non-revocation of a general release of claims. The agreement also sets forth detailed restrictive covenants, including confidentiality, noncompetition, nonsolicitation, non-interference with business relationships, nondisparagement, cooperation obligations, and return-of-property requirements, together with acknowledgements regarding his waiver and release of claims and standard procedural and governance provisions.

Filing Facts

CIK

1555280

Ticker

ZTS

Form

8K

Source Type

fda

Accession

0001193125-26-338080

Alert Tier

7